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OBJECTIVE: The INTERCEPT Blood System (IBS) for
platelets has been developed to reduce pathogen trans-
mission risks during platelet transfusions. This study
assessed the cost-effectiveness of using single-donor
platelets (SDP) and random-donor platelets (RDP)
processed with a pathogen inactivation treatment
(SDP+IBS and RDP+IBS) during orthopedic surgery,
which accounts for approximately 10% of platelets usage
in the U.S. METHODS: A decision-analytic model was
developed to simulate the possible transfusion-related
events and outcomes in three reference patients: a female
aged 60, 70, or 80 years, and undergoing a total hip
arthroplasty. Avoidance of pathogen exposure to HIV,
HCV, HBV, HTLV-I, and transfusion-related sepsis (TRS)
was incorporated in the model. Clinical outcomes were
measured by quality adjusted life-year gained (QALYs).
The direct medical costs of IBS and transfusion-related
complications were incorporated in the baseline model.
No indirect costs (e.g., work productivity losses) or trans-
fer costs (litigation) were considered. Possible beneﬁt on
reducing emerging pathogens risk was explored by incor-
porating a hypothetical HCV-like pathogen into sensitiv-
ity analyses. RESULTS: The incremental cost per QALY
gained of using SDP+IBS vs. untreated SDPs, ranged 
from $1,686,000 (at age 60)–$3,362,000 (at age 80).
Corresponding ﬁgures for RDP+IBS vs. RDPs, ranged
from $642,000–$1,404,000. Inclusion of an emerging
pathogen beneﬁt signiﬁcantly improved the cost effec-
tiveness to $423,000–$1,304,000 for SDP and
$66,000–$237,000 for RDP. Sensitivity analysis showed
that results were most sensitive to reductions in platelet
yield and case fatality rate from bacteria contamination,
but less sensitive to viral transmission risks. CONCLU-
SIONS: The cost-effectiveness of IBS in orthopedic
surgery patients appears to be comparable to that of other
widely accepted blood safety interventions (e.g. NAT
testing). Therefore, pathogen inactivation with the IBS 
for platelets should be considered to be a relatively cost-
effective strategy to improve the safety of platelet trans-
fusions and a potential insurance against the threat of
emerging pathogens.
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OBJECTIVES: In the last 25 years, the number of clini-
cal conditions Stem Cell Transplantation (SCT) is used as
a therapeutic intervention has been growing remarkably.
The emphasis in this study is on the management,
resources and economics of bleeding associated with SCT
in Germany and the United States, and the understand-
ing of the potential economic impact of NovoSeven® in
the management of such bleed. METHODS: A detailed
literature review was undertaken on bleeds associated
with SCT. Additional data were obtained from clinicians
at two leading SCT centres in Germany and one in the
United States. Resource utilisation, outcomes and cost
data were obtained from multiple sources including the
participating clinicians, local economists and personal
communications. Economic modelling techniques were
used to assess the potential impact of the addition of
NovoSeven® on current management practices.
RESULTS: In Germany, autologous, allogenic (family
related), and allogenic (un-related) SCT cost on average
€83,302, €115,954 and €172,522, respectively. The cor-
responding costs in the United States are: $84,583,
$202,474, and $303,159. Costs in the United States are
generally higher than in Europe. The additional costs of
bleeds depend on bleed site and severity. In Germany the
baseline costs of gastrointestinal and intracranial bleeds
are €32,085 and €8,684 respectively, with the addition of
NovoSeven® and associated reduction in the use of other
health care resources costs were €32,431 and €14,057. 
In the USA, the costs of bleeds vary from $5,718 to
$209,910. The additional cost of NovoSeven® may be
compensated for by a reduction in the use of blood 
products and inpatient hospitalisation. CONCLUSIONS:
Our results suggest that NovoSeven® might lead to cost
savings in certain bleeds. However, given the limited
number of bleeds managed with NovoSeven® in the
present study these results should be interpreted with
caution.
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OBJECTIVES: Treatment of severe hemophilia patients
has considerable economic implications, especially with
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increased use of prophylaxis. Few studies have analyzed
the total costs of treatment, hence we undertook this
study. METHODS: To determine total costs and trends
of treating children with severe hemophilia-A from 1978
to 1998, at the Hospital for Sick Children in Toronto, one
patient chart reviewer identiﬁed resource consumption of
all patients (n = 17). For each patient, costs for factor con-
centrate, clinic visits, physicians and healthcare profes-
sionals (physiotherapists/social workers), laboratory and
other tests (x-ray, MRI, ultrasound) and hospitalizations
were determined. Costs in Canadian dollars were taken
from standard lists and discounted at 3%. RESULTS:
Total average cost (range) was $69,322 ($14,471–
$108,294)/year/patient of which the largest part, $65,184
($8,250–$107,104), 94% (57%–99%) was accounted for
by Factor-VIII. Hospitalizations accounted for $2,396
($0–$57,063)/patient/year including drugs, nursing care
and stay. Clinic visits and physician visits were $1290
($122–$4143) and $177 ($0–$308), respectively. Health-
care professionals averaged $89 ($0–$252) and lab tests
and other tests cost $156 ($26–$226) and $31 ($4–
$70)/patient/year, respectively. The average number of
bleeds was 12.9 (2.0–22.0)/patient/year. Since 1978, the
average number of bleeds decreased by 0.71 (r2 = 0.56)/
patient/year. The average number of hospitalizations 
was 0.21 (0–4)/patient/year, in which patients stayed on
average 10.7 (1–135) days. Since 1984, the number of
hospitalizations has decreased by 0.5 hospitalizations/
patient/year (r2 = 0.74). Concurrently, the average costs
of the treatment of severe hemophiliacs have increased by
approximately $3740 (r2 = 0.62)/patient/year. Clotting
factor concentrate cost per patient increased by $4215 (r2
= 0.66)/year, of which prophylaxis accounted for $1429
(r2 = 0.60)/year, while on demand Factor-VIII costs
decreased by $497 (r2 = 0.16)/year. CONCLUSIONS:
The annual cost of hemophilia care, of $69,322 per
patient, is substantial. The number of bleeds and 
hospitalizations is decreasing while there was a clear
trend in increasing costs of treating severe hemophiliacs,
primarily associated with increasing use of prophylactic
treatment.
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OBJECTIVES: In Asia, individuals with hemophilia are
often treated with cryoprecipitate as it is considered a less
expensive option. However, the risk of acquiring blood-
borne infections is higher with cryoprecipitate than with
factor concentrates. Any acquisition cost savings that
occur with the use of cryoprecipitate may be offset by
greater total healthcare costs to treat transmissible
viruses. METHODS: A literature review was conducted
to obtain estimates of the prevalence of HIV, HBV and
HCV in the blood supply and costs of treating the sub-
sequent diseases. Data from international health organi-
zations, local experts in the treatment of hemophilia, and
the local Red Cross Society was utilized. This data forms
the basis of an economic and outcomes model for hemo-
philia treatment in this Asian country. RESULTS: Based
on the data identiﬁed, the risk of exposure to the blood-
borne infections in hemophiliacs treated with cryoprecip-
itate is substantial: 3%, 6% and 12% at 5, 10 and 20
years respectively for HIV. Risk for developing hepatitis
infection was higher. The discounted cost of treating 
the three infectious diseases is substantial. For patients
treated with cryoprecipitate total treatment costs were
$26,575 and $64,291.06 at 10 and 20 years. For patients
treated with factor concentrate equivalent costs were
$32,200 and $64,401. CONCLUSIONS: Over time, the
acquisition cost savings associated with cryoprecipitate
use, compared to factor concentrate, disappears as the
costs for treating transmissible viruses in infected patients
increases.
HEMATOLOGIC/PITUITARY DISORDERS—
Quality of Life/Preference Based Outcomes
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OBJECTIVES: To investigate whether long-term growth
hormone (GH) replacement therapy in GH deﬁcient
(GHD) adults results in improvements in Quality of Life
(QoL), patient-reported outcomes and health care uti-
lization (HCU) in the Netherlands. METHODS: The
analysis was based on 74 patients (35 men, 39 women)
and all patients were included in KIMS (Pharmacia Inter-
national Metabolic Survey)—the largest pharmacoepi-
demiological survey of GHD adults on GH therapy. Data
were available for all patients for the ﬁrst year of treat-
ment, and 2-year follow-up data were available for 38
patients. QoL was assessed using the Nottingham Health
Proﬁle (NHP) and disease-speciﬁc AGHDA question-
naire. Patient reported outcomes and data on HCU were
obtained with the Patient Life Situation Form (PLSF). Sta-
tistical analyses were performed with repeated measure-
ments technique. RESULTS: Both QoL questionnaires
showed a signiﬁcant improvement after 1 and 2 years of
GH therapy (from 20.1 ± 2.6 to 10.1 ± 2.5 for NHP, from
9.3 ± 0.82 to 7.2 ± 1.11 for AGHDA). Data collected
